The Bayer stock experienced a significant recovery, climbing to the top of the German DAX index after positive developments regarding its glyphosate business and favorable analyst commentary.

The Bayer stock, which has faced challenges in recent years, saw a notable recovery by midday, reaching the top of the German DAX index. For the first time in nearly three years, the stock surpassed the €50 mark shortly after trading began, with its value standing at approximately €52 by midday at the Frankfurt Stock Exchange. This represents a 6% increase compared to the previous day and marks a 40% gain since the beginning of the year. The surge was driven by a positive analyst report from Deutsche Bank and recent developments in Bayer’s glyphosate business.

Deutsche Bank analysts issued an optimistic assessment of Bayer, highlighting the company’s progress in refocusing on its core strengths in agriculture and pharmaceuticals. A key factor in this positive outlook was a recent ruling by the U.S. Supreme Court in Bayer’s favor regarding its glyphosate-based weed killer, Roundup. The court determined that U.S. states cannot mandate cancer warning labels on Roundup packaging, as the Environmental Protection Agency (EPA) had approved the product without such warnings. This decision could significantly reduce Bayer’s exposure to thousands of lawsuits related to glyphosate’s alleged cancer risks.

Additionally, Bayer announced plans to consolidate its U.S. glyphosate business into a new subsidiary named ‘Ruveon,’ as part of a broader restructuring of its Crop Science division. The company stated that this move aims to better address the specific demands and competitive dynamics of the U.S. market. Meanwhile, the DAX index itself showed resilience, gaining 0.9% by midday to reach approximately 25,270 points, distancing itself from the 25,000-point threshold despite losses in Asian markets, particularly in the semiconductor sector.